Advanced searches left 3/3

Methotrexate Rheumatoid Arthritis - Crossref

Summarized by Plex Scholar
Last Updated: 02 May 2022

* If you want to update the article please login/register

P215 In a treatment-naïve, early rheumatoid arthritis cohort, baseline ultrasound power Doppler synovitis and tenosynovitis are highly associated with remission when treated with first line etanercept + methotrexate (MTX) but not MTX alone

We wanted to investigate specifically for an association of baseline PDUS and PD tenosynovitis with subsequent clinical participation in VEDERA, as well as comparing the two treatment groups for this research. Methods The ‘VEDERA' trial randomly selected 120 patients from a new-onset RA patients to either first-line etanercept+methotrexate or methotrexate therapy target regime with increase in DAS28ESR remission at week 24. Overall, baseline PDUS was linked to week 24 remission and baseline PDTS was associated with week 24, 48, and 48 remission between week 24 and 48. In comparison to an absence of affiliation in the MTX-TT group, PDTS was also associated with a high OR for week 48 remission in the ETN+MTX group. Conclusion Baseline PDUS and PDTS are related to remission in early RA patients treated with TNF-inhibitor therapy. These steps may be able to stratify patients early for TNF bDMARD to achieve the target of clinical remission in RA.

Source link: https://doi.org/10.1093/rheumatology/keac133.214


P090 Clinical prediction models for methotrexate treatment outcomes in rheumatoid arthritis patients: a review of existing models and summary of their limitations

According to NICE's guidelines, Methotrexate is the most commonly used first line therapy for rheumatoid arthritis. MTX has several advantages over other treatments, including safety and low cost, but after 6 months, around 40% of patients are classified as non-responders. Patients at high risk of poor outcomes must therefore be identified, so that patients could be rushed to alternative therapies to improve their clinical outcomes and quality of life. This study also sought to identify and summarise multivariable prediction models of MTX treatment results in biologic-nave adult RA patients, as well as their methodological properties. The results were stratified by outcome definition, and results on predictors, and model validation were extracted from the study. AEs were also included in the composite result with disease activity in three studies, 1 investigated both effects in separate studies, and only 1 anticipated potential risks to their primary outcome. In five studies, missing data was appropriately handled using multiple imputation techniques, while others used single imputation or complete case analysis, resulting in potentially biased risk estimates or failure to report how they handled missing data. Conclusions This paper summarizes recent prediction models of MTX treatment outcomes in RA. MTX therapy results are at a high risk of bias, and should not be used for establishing risk stratification for RA treatment decisions without considering these topics.

Source link: https://doi.org/10.1093/rheumatology/keac133.089


P068 Monitoring of methotrexate blood toxicity during the COVID-19 pandemic for patients with rheumatoid arthritis: data from the Greater Manchester Care Record

Abstract Background/Aims The current British Society for Rheumatology's guiding line calls for 3-month blood testing for patients on methotrexate-based chemotherapy whose disease, drug dosage, and blood findings are stable, but evidence for this recommendation is lacking. The study's objectives were to determine: 1 interval length between blood tests during the pandemic and 2 whether long intervals were associated with abnormal blood test findings in patients with rheumatoid arthritis prescribed methotrexate to establish: Methods Data came from the Greater Manchester Care Record, a database that holds electronic health information from both primary and secondary care for residents across Greater Manchester, Greater Manchester. a diagnosis of RA; regular blood sampling =91 days between blood tests and regular methotrexate prescriptions in the year leading up to the pandemic 01/03/2019-01/03/2020. During the pandemic and a median interval of 34-84 days IQR: 1011 patients met the inclusion criteria, with a median of 5 blood tests interquartile range IQR: 3-7. 115 11. 4% residents had a long syndromic period, but no subsequent blood test was performed before the study's end date, median 120 days [IQR: 104-150]. Conclusion Nearly two-thirds of patients on stable methotrexate had at least one long interval, and one out of ten had a long time with no subsequent blood test. Initial testing results of tests show that methotrexate blood toxicity in those with longer blood test intervals during the pandemic does not increase. Further research is required to determine whether those with lengthy intervals represent a group at a higher risk of getting less frequent blood tests would be more appropriate.

Source link: https://doi.org/10.1093/rheumatology/keac133.067


Exhaled nitric oxide in early rheumatoid arthritis and effects of methotrexate treatment

Patients with established rheumatoid arthritis and disease-modifying therapies have reduced nitric oxide levels in the algeolar compartment and in the airway wall, but also higher diffusion rates for NO in the airways compared to similar controls. The objective of the present research was to investigate the NO lung dynamics in patients with new onset RA before and after immune suppression with methotrexate therapy. With the Disease Activity Score for 28 joints, clinical disease prevalence was monitored. C A NO was lower in RA patients 1. 6 ppb compared to the control subjects' 2. 3 ppb, p = 0. 007. However, D aw NO was also lower in the RA patients 55 ppb relative to control subjects, p 0. 001, but D aw NO was also higher 17 mL/s and 9 mL/s respectively, p 0. 001, but D aw NO was also lower in the RA patients' 55 ppb, p 0. 001, p 0. 001, p 0. 001, respectively, p a.

Source link: https://doi.org/10.1038/s41598-022-10334-5


Gamma-glutamyl hydrolase gene polymorphisms – another way to predict methotrexate efficacy in rheumatoid arthritis

The new treatment plan for rheumatoid arthritis has been developed within the framework of the European League Against Rheumatism's "treatment to achieve the target. " Genetic testing for drug therapy success has gained traction in recent years, owing to individual differences in enzyme systems that control various stages of drug biotransformation. After analyzing more than a dozen of single nucleotide polymorphisms within the folate cycle genes that regulate metabolism methotrexate metabolism as well as its mechanism of action, a personalized approach to treatment of rheumatoid arthritis may be implemented. We wanted to see if there was a correlation between therapeutic response to methotrexate and -401CT SNP in the GGH gene, which coordinates the procedures of extracellular methotrexate transport in our research. Next, all patients from selected groups underwent molecular genetic testing for GGH-401CT SNP by using real-time polymerase chain reactions.

Source link: https://doi.org/10.46235/1028-7221-333-ghg


Risk of herpes zoster in patients with rheumatoid arthritis in the biologics era from 2011 to 2015 and its association with methotrexate, biologics, and corticosteroids

BACTROCT aims To elucidate the occurrence and risk factors of herpes zoster in patients with rheumatoid arthritis in the biologics period. Methods We found the prevalence of HZ in the RA patients participating in the Institute of Rheumatology, Rheumatoid Arthritis surveys from 2011 to 2015 by reviewing medical data. Among the 7815 patients who contributed to 25,863 patient years of observation, 340 HZ infections in 309 patients were reported. HZ's risk factors include age, ten years, Japanese version of the Health Assessment Questionnaire score of 0. 5–1. 5, methotrexate use, and biologic use.

Source link: https://doi.org/10.1093/mr/roab026


Polymorphisms and Pharmacogenomics for the Clinical Efficacy of Methotrexate in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis

Several of the key genes have been studied to determine the relationship between gene polymorphisms and MTX use in RA patients, but mixed findings have been reported. a 67C > T, ATIC 347C > G, SLC19A1 G > G, RFC-1 80G T, MTHFR 1298A > C, ATIC 347C > G, A1 G > G, A A, SLC19A1 G > A > A, A: MTHFR 677C > G, ABCB1 3435 C > T, and ABCB1 3435C > T, A tr However, polymorphisms not related to meta-analysis may not have been present in larger cohorts or a rigorous manner, which may lead to more accurate results for the effect of the gene polymorphisms on the MTX response.

Source link: https://doi.org/10.1038/srep44015


Cuscuta Chinensis potentiate the effect of methotrexate in Rheumatoid Arthritis Induced Rats.

History of Rheumatoid arthritis is a chronic inflammatory disease attributed to a lack of immune function. Cuscuta Chinensis is a parasitic plant that grows in proximity to other plants in order to absorb nutrients and water. C. Chinensis is a manufacturer of a variety of pharmacological activates. Methods: Complete Freund's Adjuvant injection was used to induce rheumatoid arthritis in male albino rats' foot pad. Following group 1's classification as a normal control group, group 1 was classified as a positive control group, group 2 was considered as positive control arthritis, group 3 was treated with methotrexate, and group 4 was treated with MTX and C. Chinensis extracts, following group 1's diagnosis as a normal control group, group 1 was divided into four groups, according to group 4 who was divided as positive control arthritis, group 2 was classified as positive control arthritis, group 1 was divided into group 2 group 2 patients were divided by group 1's symptomatic control group 1's, group 1'sis hypoactive control group 1 with positive control arthritis, group 2'syasymptomatic control arthritis, group 2'sy, group 2 treated with methotrexogene metabolitis rabensis treatment of C. On day 14 of immunization administration, treatments began and lasted for 21 days, and at the end of the trial, all animals were sacrificed and serum was collected. MMP3, VEGF, serum MMP3, and serum SOD have all decreased significantly, and significantly increased serum SOD levels.

Source link: https://doi.org/10.32947/ajps.v20i4.771


Efficacy and safety of iguratimod combined with methotrexate vs. methotrexate alone in rheumatoid arthritis

Abstract In rheumatoid arthritis compared to MTX alone, the current systematic review and meta-analysis aims to determine the efficacy and safety of iratimod combined with methotrexate versus MTX alone. In PubMed, Cochrane Library, Embase, the Chinese National Knowledge Infrastructure, and WanFang Statistics, two independent investigators searched for original randomized controlled trials related to the combination of IGU and MTX in RA published before November 1, 2019. In the IGU + MTX group, the risk of ACR20, ACR50, and ACR70 were higher than in the MTX alone group, with a pooled relative risk for ACR20, ACR50, and ACR70 of 1. 40, 2. 09, and 2. 24, respectively. The combined therapy is an affordable, safe, and cost-effective treatment option for patients who do not respond well to methotrexate alone or for patients who are unable to afford costly biologics with no demonstrated effectiveness.

Source link: https://doi.org/10.1007/s00393-020-00944-7


Methotrexate significantly reduces the humoral vaccination response against SARS-CoV-2 in older but not younger patients with rheumatoid arthritis

In patients under the age of 70 years, MTX patients had a significantly reduced moral reaction to vaccination in the oldest patient subgroup, whereas non-MTX patients had a maximum immune response in 76 percent of cases, although this percentage was down to 53 percent in study participants on MTX medications. Since vaccination against SARS-CoV-2, the older age in patients with rheumatoid arthritis in combination with methotrexate results in a significantly reduced humoral response in patients with rheumatoid arthritis in combination with methotrexate findings in a significant reduction in humor.

Source link: https://doi.org/10.1007/s00296-022-05123-2

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions